Company Filing History:
Years Active: 2005
Title: Ma Teresa Lopez Hernandez: Innovator in Virus-Inactivated Human Gammaglobulin G Production
Introduction
Ma Teresa Lopez Hernandez is a notable inventor based in Badalona, Spain. She has made significant contributions to the field of biopharmaceuticals, particularly in the production of virus-inactivated human gammaglobulin G. Her innovative approach has the potential to enhance the safety and efficacy of immunoglobulin therapies.
Latest Patents
Ma Teresa holds a patent for a process that involves the production of virus-inactivated human gammaglobulin G. This process includes extracting gammaglobulin from a fraction isolated by ethanol fractionation in the presence of a carbohydrate. The method further reduces contaminants using PEG and applies an anionic resin exchange column. The resulting effluent undergoes ultrafiltration to reduce PEG content and is concentrated for optional treatments at an acid pH. The viral inactivation steps include pasteurization and solvent/detergent treatment, followed by precipitation and washing with PEG to eliminate any chemical viral inactivation reagents. The final purification steps involve solubilization, pH change, and ultrafiltration to ensure a safe and effective product.
Career Highlights
Ma Teresa is currently associated with Probitas Pharma S.A., where she continues to advance her research and development efforts. Her work is pivotal in the biopharmaceutical industry, focusing on improving the safety of immunoglobulin products.
Collaborations
She collaborates with esteemed colleagues such as Pere Ristol Debart and Francisco Rabaneda Gimenez, contributing to a dynamic research environment that fosters innovation and excellence in biopharmaceutical development.
Conclusion
Ma Teresa Lopez Hernandez exemplifies the spirit of innovation in the biopharmaceutical sector. Her contributions to the production of virus-inactivated human gammaglobulin G are significant and reflect her commitment to enhancing patient safety and treatment efficacy.